These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37920145)

  • 1. A multivariate curve resolution analysis of multicenter proton spectroscopic imaging of the prostate for cancer localization and assessment of aggressiveness.
    Stamatelatou A; Bertinetto CG; Jansen JJ; Postma G; Selnaes KM; Bathen TF; Heerschap A; Scheenen TWJ;
    NMR Biomed; 2024 Mar; 37(3):e5062. PubMed ID: 37920145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Quality 3-Dimensional 1H Magnetic Resonance Spectroscopic Imaging of the Prostate Without Endorectal Receive Coil Using A Semi-LASER Sequence.
    Tayari N; Steinseifer IK; Selnæs KM; Bathen TF; Maas MC; Heerschap A
    Invest Radiol; 2017 Oct; 52(10):640-646. PubMed ID: 28632688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study.
    Scheenen TW; Fütterer J; Weiland E; van Hecke P; Lemort M; Zechmann C; Schlemmer HP; Broome D; Villeirs G; Lu J; Barentsz J; Roell S; Heerschap A
    Invest Radiol; 2011 Jan; 46(1):25-33. PubMed ID: 21188832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate.
    Fütterer JJ; Scheenen TW; Heijmink SW; Huisman HJ; Hulsbergen-Van de Kaa CA; Witjes JA; Heerschap A; Barentsz JO
    Invest Radiol; 2007 Feb; 42(2):116-22. PubMed ID: 17220729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
    Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Wright AJ; Barentsz JO; Heerschap A; Scheenen TW
    Eur Urol; 2011 Nov; 60(5):1074-80. PubMed ID: 21419565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach.
    Maas MC; Litjens GJS; Wright AJ; Attenberger UI; Haider MA; Helbich TH; Kiefer B; Macura KJ; Margolis DJA; Padhani AR; Selnæs KM; Villeirs GM; Fütterer JJ; Scheenen TWJ
    Invest Radiol; 2019 Jul; 54(7):437-447. PubMed ID: 30946180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supervised risk predictor of central gland lesions in prostate cancer using
    Gholizadeh N; Greer PB; Simpson J; Fu C; Al-Iedani O; Lau P; Heerschap A; Ramadan S
    J Magn Reson Imaging; 2019 Dec; 50(6):1926-1936. PubMed ID: 31132193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate MRSI predicts outcome in radical prostatectomy patients.
    Zakian KL; Hatfield W; Aras O; Cao K; Yakar D; Goldman DA; Moskowitz CS; Shukla-Dave A; Tehrani YM; Fine S; Eastham J; Hricak H
    Magn Reson Imaging; 2016 Jun; 34(5):674-81. PubMed ID: 26821278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.
    Kobus T; Vos PC; Hambrock T; De Rooij M; Hulsbergen-Van de Kaa CA; Barentsz JO; Heerschap A; Scheenen TW
    Radiology; 2012 Nov; 265(2):457-67. PubMed ID: 22843767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple and broadly applicable automatic quality control for 3D
    Tayari N; Obels J; Kobus T; Scheenen TWJ; Heerschap A
    Magn Reson Med; 2019 May; 81(5):2887-2895. PubMed ID: 30506721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-line Raman spectroscopy combined with multivariate curve resolution-alternating least squares (MCR-ALS) to investigate the synthesis mechanism of 3,5-diamino-1,2,4-triazole (DAT).
    Fu H; Li M; Guo M; Tang H; Zhang T; Li H
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Mar; 289():122231. PubMed ID: 36527968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
    Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
    Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection.
    Gholizadeh N; Greer PB; Simpson J; Goodwin J; Fu C; Lau P; Siddique S; Heerschap A; Ramadan S
    J Biomed Sci; 2021 Jul; 28(1):54. PubMed ID: 34281540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated vs. manual pattern recognition of 3D (1)H MRSI data of patients with prostate cancer.
    Zechmann CM; Menze BH; Kelm BM; Zamecnik P; Ikinger U; Giesel FL; Thieke C; Delorme S; Hamprecht FA; Bachert P
    Acad Radiol; 2012 Jun; 19(6):675-84. PubMed ID: 22578226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.
    Jung JA; Coakley FV; Vigneron DB; Swanson MG; Qayyum A; Weinberg V; Jones KD; Carroll PR; Kurhanewicz J
    Radiology; 2004 Dec; 233(3):701-8. PubMed ID: 15564406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
    Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
    Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of 3D 1H MR spectroscopic imaging of the prostate at 1.5T.
    Lagemaat MW; Zechmann CM; Fütterer JJ; Weiland E; Lu J; Villeirs GM; Holshouser BA; van Hecke P; Lemort M; Schlemmer HP; Barentsz JO; Roell SO; Heerschap A; Scheenen TW
    J Magn Reson Imaging; 2012 Jan; 35(1):166-73. PubMed ID: 21960013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrow band deformable registration of prostate magnetic resonance imaging, magnetic resonance spectroscopic imaging, and computed tomography studies.
    Schreibmann E; Xing L
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):595-605. PubMed ID: 15890605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.